A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis.

@article{Hewitt2006API,
  title={A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis.},
  author={Maureen R Hewitt and Weijing Sun and Daniel G. Haller and Kristine Mykulowycz and Catherine M E Tuite and Mark Allen Rosen and Michael C. Soulen and Millie Caparro and Bruce J. Giantonio and Kim M. Olthoff},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={14098}
}
14098 Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third leading cause of cancer-related death, with increasing incidence in USA. Most patients with HCC are unsuitable for surgery. There is no generally accepted 'standard' chemotherapy regimen for HCC because of the heterogeneity of disease and poor liver function in many patients. Continuous efforts have been made for investigating effective and tolerable therapy for patients with advanced HCC… CONTINUE READING